CA2299425A1 — Novel exendin agonist compounds
Assigned to Amylin Pharmaceuticals LLC · Expires 1999-02-18 · 27y expired
What this patent protects
Novel exendin agonist compounds are provided. These compounds are useful in treating Type I and II diabetes and conditions which would be benefited by lower plasma glucose and delaying and/or slowing gastric emptying.
USPTO Abstract
Novel exendin agonist compounds are provided. These compounds are useful in treating Type I and II diabetes and conditions which would be benefited by lower plasma glucose and delaying and/or slowing gastric emptying.
Drugs covered by this patent
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.